Printer Friendly

U.S ALCOHOL TESTING DIVISION COMMENCES JOINT AGREEMENT WITH ABBOTT DIAGNOSTICS

 RANCHO CUCAMONGA, Calif., May 27 /PRNewswire/ -- Gary S. Wolff, chief financial officer of U.S. Alcohol Testing of America Inc. (AMEX: AAA) (USAT), announced today that its division, Biochemical Toxicology Laboratory (BIOTOX), has commenced a joint agreement with Abbott Diagnostics, a division of Abbott Laboratories (ABBOTT). Through this agreement, ABBOTT will perform the marketing function for BIOTOX's methadone testing program, and BIOTOX has agreed to perform tests using the ABBOTT analysis system. The equipment will be supplied and maintained by ABBOTT.
 BIOTOX recently became only the fourth laboratory certified by the State of California to perform analysis for methadone programs, putting BIOTOX and ABBOTT in direct competition with Pharmchem, MetWest, and San Diego Reference Laboratories.
 Under statues in the California Health and Safety Code, and regulations contained in the California Administrative Code, laboratories performing drug analysis for the federally funded methadone program must be certified by the State Department of Health Services. Requirements for obtaining this certification include proficiency testing of blind samples, procedural documentation, and an on-site inspection by state officials.
 ABBOTT, located in a Chicago suburb, is a Fortune 50 company and is the largest diagnostics company in the world. A market study conducted by the Medical Examiners Research Group (MLO Magazine) comparing various abused drug testing manufacturers, ranked ABBOTT No. 1 in reliability, availability, value and service.
 BIOTOX and ABBOTT believe that their joint effort will allow them to provide methadone clinics with faster turnaround time, more accurate results with greater clinical value, and better personal service.
 USAT purchased the assets of BIOTOX, an independent clinical and forensic laboratory engaged in the business of drug testing in October 1992. The company believes that the methadone license will create expansion of revenues within this division.
 U.S. Alcohol Testing of America manufactures and markets alcohol breath testing equipment to law enforcement agencies and industry. Its BIOTOX division is a licensed clinical laboratory performing forensic drug testing services.
 -0- 5/27/93
 /CONTACT: Gary S. Wolff, CFO of U.S. Alcohol Testing of America, 909-466-8378/
 (AAA)


CO: U.S. Alcohol Testing of America Inc.; Biochemical Toxicology
 Laboratory; Abbott Laboratories ST: California IN: MTC SU: JVN


JB-EH -- LA020 -- 2967 05/27/93 12:48 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1993
Words:365
Previous Article:EDISON OFFERS REBATES ON NEW, ENERGY EFFICIENT REFRIGERATORS
Next Article:KEVIN MESSICK NAMED PRESIDENT OF NEWLY FORMED JOEL SCHUMACHER PRODUCTIONS
Topics:


Related Articles
EPITOPE ANNOUNCES GLOBAL MARKETING/MANUFACTURING PACTS AT SHAREHOLDERS' MEETING
EDITEK, INC. AND RHONE-POULENC DIAGNOSTICS, LTD. ESTABLISH JOINT VENTURE
HOFFMANN-LA ROCHE AND ABBOTT AGREE TO LICENSE KEY PATENTS FOR DIAGNOSTIC APPLICATIONS OF GENE AMPLIFICATION TECHNOLOGIES
ABBOTT AND BECKMAN'S SMITHKLINE DIAGNOSTICS ANNOUNCE AGREEMENT ON TEST FOR ULCERS
ABBOTT REPORTS INCREASE IN SALES AND EARNINGS IN 1995; SALES RISE 9.4 PERCENT TO $10.0 BILLION, EPS UP 13.4 PERCENT
ABBOTT LABORATORIES ACQUIRES CONTROL OF MEDISENSE, INC.
Abbott Laboratories to Acquire French Maker of Clinical Chemistry Analyzers
Abbott Laboratories to Acquire International Murex Technologies Corporation For $234 Million or $13 Per Share
Abbott Laboratories and Adeza Biomedical Announce Agreement To Market Test for Preterm Labor.
Abbott Announces New Point-Of-Care Agreement With Novation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters